|Bid||1.5000 x 1200|
|Ask||1.5100 x 800|
|Day's Range||1.4900 - 1.5350|
|52 Week Range||1.1500 - 3.6700|
|Beta (5Y Monthly)||0.75|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Some CASI Pharmaceuticals, Inc. (NASDAQ:CASI) shareholders are probably rather concerned to see the share price fall...
By Beth Senko, CFA NASDAQ:CASI READ THE FULL CASI RESEARCH REPORT CASI Pharmaceuticals (NASDAQ:CASI) signaled a shift in its business strategy in March – focusing its efforts on its hematology franchise and deemphasizing its ANDA portfolio. This change scales back CASI’s initial broad-reaching goal to be the leading provider of high quality proprietary, licensed and ANDA pharmaceuticals to the
Earlier today, CASI issued a press release providing the details of our financial results for the quarter ended June 30, 2020, as well as a corporate and clinical update. The press release is available in the Investor Relations section of our website at casipharmaceuticals.com.